Controversial Ginkgo Will Team With Persephone On Bacterial Delivery Of Microbial Therapies
Executive Summary
Deal Snapshot: In its third biopharma collaboration this year, Ginkgo will apply its genetic engineering technologies to using Bacteroides for stable delivery of microbiome medicines.
You may also be interested in...
Deal Watch: Dragonfly Adds Gilead To Its List Of Big-Name Partners
AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.
Deal Watch: Jazz Breaks Into Immuno-Oncology Via Licensing Pact With Werewolf
AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.
Deal Watch: Bristol, Pfizer Lead Off J.P. Morgan Week With Two Deals Apiece
Despite no mega-deals (yet), the J.P. Morgan Healthcare Conference’s first day brings the usual flurry of deals, including a pair of tie-ups each for Bristol and Pfizer. BioNTech moves into cancer with Crescendo.